Biolexis Therapeutics to Present Two Pioneering Abstracts at Upcoming Scientific Conference

AMERICAN FORK, Utah, June 21, 2024 - Biolexis, a leading biopharmaceutical company, is set to reveal two groundbreaking abstracts at the upcoming American Diabetes Association conference, which will take place from June 21-24, 2024. These abstracts, entitled "Discovery of a Potent, Orally Efficacious Small Molecule Agonist of Glucagon-Like Peptide-1 (GLP-1) Receptor" (Abstract 1139-P) and "Development of MLX-0871, a Potent, Isoform-Selective, Orally Available AMPK Activator, Displays Efficacy in Obese and Type 2 Diabetes Models" (Abstract 1145-P), highlight Biolexis' innovative research in the field of metabolic diseases.

Abstract 1139-P discusses the discovery of MLX-7006, an orally efficacious small molecule that acts as a potent agonist of the GLP-1 receptor. This compound exhibits significant potential in treating metabolic disorders, presenting a novel pathway for therapeutic interventions. On the other hand, Abstract 1145-P focuses on MLX-0871, an isoform-selective, orally available AMPK activator. This compound has demonstrated remarkable efficacy in preclinical models of obesity and type 2 diabetes, showcasing its promise as a new treatment option for these prevalent conditions.

Dr. Hariprasad Vankayalapati, Co-Founder and Chief Scientific Officer of Biolexis, expressed his excitement over these advancements. He noted, "We are incredibly excited about the development of MLX-0871 and MLX-7006. These oral small molecules represent significant advancements in our mission to develop innovative treatments for metabolic diseases." Dr. David Bearss, Co-Founder of Biolexis, added, "The efficacy demonstrated in our preclinical studies is promising, and we look forward to advancing these compounds through clinical trials. We aim to bring each of these assets to the clinic by the second quarter of early 2025."

Both abstracts will be presented on Monday, June 24th, allowing attendees to gain detailed insights into the cutting-edge research and promising findings achieved by the Biolexis team.

Biolexis Therapeutics is committed to addressing the urgent global challenges posed by diabetes, obesity, and other metabolic disorders. Utilizing advanced technologies and a strong dedication to scientific innovation, the company aims to transform the landscape of treatment options available to patients worldwide. Biolexis' robust pipeline is driven by an unwavering pursuit of novel therapeutic approaches, aiming not only to manage but also to potentially reverse the debilitating effects of these widespread and complex conditions.